US2475569A
(en)
|
1944-02-07 |
1949-07-05 |
American Cyanamid Co |
Substituted pyridine compound
|
US5650270A
(en)
|
1982-02-01 |
1997-07-22 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
US4650750A
(en)
|
1982-02-01 |
1987-03-17 |
Giese Roger W |
Method of chemical analysis employing molecular release tag compounds
|
US4709016A
(en)
|
1982-02-01 |
1987-11-24 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
US5516931A
(en)
|
1982-02-01 |
1996-05-14 |
Northeastern University |
Release tag compounds producing ketone signal groups
|
JP4078074B2
(ja)
|
1999-12-10 |
2008-04-23 |
ファイザー・プロダクツ・インク |
ピロロ[2,3−d]ピリミジン化合物
|
DE60217322T2
(de)
|
2001-04-27 |
2007-10-04 |
Zenyaku Kogyo K.K. |
Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
WO2004019973A1
(en)
|
2002-08-14 |
2004-03-11 |
Atugen Ag |
Use of protein kinase n beta
|
SG160211A1
(en)
|
2003-04-03 |
2010-04-29 |
Semafore Pharmaceuticals Inc |
Pi-3 kinase inhibitor prodrugs
|
CA2527583C
(en)
|
2003-05-30 |
2013-12-17 |
Giorgio Attardo |
Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
|
US7129260B2
(en)
*
|
2003-06-02 |
2006-10-31 |
Abbott Laboratories |
Isoindolinone kinase inhibitors
|
AU2004257167B2
(en)
|
2003-07-03 |
2012-03-29 |
The Trustees Of The University Of Pennsylvania |
Inhibition of Syk kinase expression
|
CN101031569B
(zh)
|
2004-05-13 |
2011-06-22 |
艾科斯有限公司 |
作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
|
GB0419160D0
(en)
*
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
EP2161275A1
(en)
|
2005-01-19 |
2010-03-10 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
EP2343320B1
(en)
|
2005-03-25 |
2017-10-25 |
GITR, Inc. |
Anti-gitr antibodies and uses thereof
|
US7745641B2
(en)
*
|
2005-04-19 |
2010-06-29 |
Kyowa Hakko Kirin Co., Ltd. |
Nitrogen-containing heterocyclic compound
|
KR101509440B1
(ko)
|
2005-05-12 |
2015-04-07 |
애브비 바하마스 리미티드 |
아폽토시스 촉진제
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
MX2007015942A
(es)
|
2005-07-01 |
2008-03-07 |
Medarex Inc |
Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
CN103819416A
(zh)
|
2005-10-07 |
2014-05-28 |
埃克塞里艾克西斯公司 |
N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
|
WO2007053452A1
(en)
|
2005-11-01 |
2007-05-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
HUE030235T2
(en)
|
2005-12-13 |
2017-04-28 |
Incyte Holdings Corp |
Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
CN101472930B
(zh)
|
2006-04-26 |
2011-12-14 |
霍夫曼-拉罗奇有限公司 |
用作PI3K抑制剂的噻吩并[3,2-d]嘧啶的衍生物
|
EP2526933B1
(en)
|
2006-09-22 |
2015-02-25 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
WO2008047831A1
(fr)
*
|
2006-10-17 |
2008-04-24 |
Kyowa Hakko Kirin Co., Ltd. |
Inhibiteurs de JAK
|
ES2557930T3
(es)
|
2007-03-12 |
2016-01-29 |
Ym Biosciences Australia Pty Ltd |
Compuestos de fenilaminopirimidina y usos de los mismos
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
ES2591281T3
(es)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
CN101932325B
(zh)
|
2007-11-30 |
2014-05-28 |
新联基因公司 |
Ido抑制剂
|
GB0724342D0
(en)
|
2007-12-13 |
2008-01-30 |
Prolysis Ltd |
Anitbacterial compositions
|
ES2602577T3
(es)
|
2008-03-11 |
2017-02-21 |
Incyte Holdings Corporation |
Derivados de azetidina y ciclobutano como inhibidores de JAK
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
TWI686405B
(zh)
|
2008-12-09 |
2020-03-01 |
建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
TW201100441A
(en)
*
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-gitr 항체
|
US8722720B2
(en)
|
2009-10-28 |
2014-05-13 |
Newlink Genetics Corporation |
Imidazole derivatives as IDO inhibitors
|
ES2722300T3
(es)
|
2009-12-10 |
2019-08-09 |
Hoffmann La Roche |
Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
|
PH12018501083A1
(en)
|
2010-03-04 |
2019-02-18 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
CN102918060B
(zh)
|
2010-03-05 |
2016-04-06 |
霍夫曼-拉罗奇有限公司 |
抗人csf-1r抗体及其用途
|
US9221910B2
(en)
|
2010-03-05 |
2015-12-29 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R
|
US8314120B2
(en)
|
2010-03-30 |
2012-11-20 |
Abbott Gmbh & Co. Kg |
Small molecule potentiators of metabotropic glutamate receptors
|
SI2566517T1
(sl)
|
2010-05-04 |
2019-01-31 |
Five Prime Therapeutics, Inc. |
Protitelesa, ki vežejo CSF1R
|
EP2614082B1
(en)
|
2010-09-09 |
2018-10-03 |
Pfizer Inc |
4-1bb binding molecules
|
BR122021026169B1
(pt)
|
2010-12-09 |
2023-12-12 |
The Trustees Of The University Of Pennsylvania |
Uso de uma célula
|
NO2694640T3
(pt)
|
2011-04-15 |
2018-03-17 |
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
WO2013086397A1
(en)
|
2011-12-08 |
2013-06-13 |
Array Biopharma Inc. |
Urea compounds as gka activators
|
WO2013087699A1
(en)
|
2011-12-15 |
2013-06-20 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
CA2861122A1
(en)
|
2012-02-06 |
2013-08-15 |
Genentech, Inc. |
Compositions and methods for using csf1r inhibitors
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
BR112014028013A2
(pt)
|
2012-05-11 |
2018-02-27 |
Five Prime Therapeutics Inc |
métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
US20140079699A1
(en)
|
2012-08-31 |
2014-03-20 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
KR102233252B1
(ko)
|
2012-11-08 |
2021-03-26 |
브리스톨-마이어스 스큅 컴퍼니 |
IL-12, IL-23 및/또는 IFNα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
|
MY175448A
(en)
|
2012-11-08 |
2020-06-29 |
Bristol Myers Squibb Co |
Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifna responses
|
JP6458038B2
(ja)
|
2013-12-10 |
2019-01-23 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なイミダゾピリダジン化合物
|
ES2921874T3
(es)
|
2014-02-28 |
2022-09-01 |
Nimbus Lakshmi Inc |
Inhibidores de TYK2 y usos de los mismos
|
WO2016101119A1
(en)
|
2014-12-23 |
2016-06-30 |
Merck Sharp & Dohme Corp. |
Fused heteroaryl derivatives as orexin receptor antagonists
|
KR101660863B1
(ko)
*
|
2015-04-03 |
2016-09-28 |
주식회사 녹십자 |
IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물
|
KR101846475B1
(ko)
*
|
2015-04-27 |
2018-04-09 |
주식회사 녹십자 |
TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
|
PL3322711T3
(pl)
*
|
2015-06-25 |
2021-10-25 |
University Health Network |
Inhibitory hpk1 i sposoby ich zastosowania
|
EP3402799B1
(en)
|
2016-01-15 |
2022-05-04 |
Enanta Pharmaceuticals, Inc. |
Heterocyclic compounds as rsv inhibitors
|
WO2017147328A1
(en)
*
|
2016-02-23 |
2017-08-31 |
Portola Pharmaceuticals, Inc. |
Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
US20180072741A1
(en)
*
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyrimidine compounds and uses thereof
|
EP3523289A1
(en)
*
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
JP7025426B2
(ja)
*
|
2016-11-30 |
2022-02-24 |
アリアド ファーマシューティカルズ, インコーポレイテッド |
造血前駆体キナーゼ1(hpk1)阻害剤としてのアニリノピリミジンas
|
KR102314286B1
(ko)
|
2016-12-16 |
2021-10-21 |
화이자 인코포레이티드 |
Glp-1 수용체 작용제 및 이의 용도
|
WO2018183956A1
(en)
*
|
2017-03-30 |
2018-10-04 |
Genentech, Inc. |
Naphthyridines as inhibitors of hpk1
|
CN109721620B
(zh)
*
|
2017-10-27 |
2022-05-13 |
药捷安康(南京)科技股份有限公司 |
Hpk1抑制剂及其用途
|
JP7167146B2
(ja)
*
|
2017-11-06 |
2022-11-08 |
ブリストル-マイヤーズ スクイブ カンパニー |
Hpk1阻害剤として有用なイソフラノン化合物
|
WO2019164847A1
(en)
*
|
2018-02-20 |
2019-08-29 |
Incyte Corporation |
Indazole compounds and uses thereof
|
US10745388B2
(en)
*
|
2018-02-20 |
2020-08-18 |
Incyte Corporation |
Indazole compounds and uses thereof
|
US20200038378A1
(en)
|
2018-04-01 |
2020-02-06 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
KR20210084537A
(ko)
|
2018-10-29 |
2021-07-07 |
베링거 인겔하임 인터내셔날 게엠베하 |
피리디닐 설폰아미드 유도체, 약제학적 조성물 및 이의 용도
|
CA3150108A1
(en)
*
|
2019-09-13 |
2021-03-18 |
Neelu Kaila |
HPK1 ANTAGONISTS AND THEIR USES
|
EP4168411A1
(en)
*
|
2020-06-22 |
2023-04-26 |
PMV Pharmaceuticals, Inc. |
Methods and compounds for restoring mutant p53 function
|